Abstract:
PROBLEM TO BE SOLVED: To provide materials involved in the control of the circulatory system, more specifically, to provide a recombinant material useful for the production of a thrombin receptor, to provide use of the receptor as a diagnostic tool, and to provide a therapeutic agent which either stimulates or blocks thrombin receptor activation and diagnostic compositions relevant to the receptor. SOLUTION: The materials include a mutant thrombin, a DNA molecule, and a recombinant host cell; wherein the mutant thrombin, producible in a recombinant way, is such that the 57- and/or 99- and/or 205-position(s) is (are) different from that(those) in a wild-type thrombin b-chain, the DNA molecule has an expression system capable of producing the thrombin in a host when transformed to the recombinant host and includes a DNA sequence encoding the thrombin linked agonistically to an abnormal regulatory sequence so that the expression system is operable in the host, and the recombinant host cell is subject to transformation by the expression system. COPYRIGHT: (C)2003,JPO
Abstract:
PROBLEM TO BE SOLVED: To provide another method of antithrombosis treatment by specifically inhibiting the bonding of vWF to a GPIb-IX complex containing platelets. SOLUTION: A DNA molecule composition comprising DNA molecules each containing a sequence encoding a platelet anti-adhesive peptide obtained from snake venoms selected from the following group; Agkistrodon, Bitis, Bothrops, Cerastes, Crotalus, C, Echis carinatus sochurecki, Eristicophis macmahoni, Pseudocerastes persicus, Sistrurus, Trimeresurus, and Vipera.
Abstract:
Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds of formula (I) are useful in vitro or in vivo for preventing or treating coagulation disorders.
Abstract:
The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract:
Novel compounds of formula (I), including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa is described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
Abstract:
Novel quaternary amine-containing compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
Abstract:
Novel compounds of formula in which A is a substituted or unsubstituted phenyl, naphthyl or monocyclic heterocyclic ring, D is a substituted or unsubstituted phenyl or aromatic six-membered heterocyclic ring, K is a substituted or unsubstituted phenyl, naphthyl or bicyclic heterocyclic ring, and the other variables are as defined in the claims, their salts and other derivatives and compositions related thereto having activity against mammalian Factor Xa are disclosed. The coumpounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Abstract:
The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and slats or prodrugs thereof. The invention further provides a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases comprising administering an effective amount of a compound according to the invention to a patient in need thereof.
Abstract:
The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibitng kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract:
Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.